Case Report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion
Ensartinib may provide a new therapeutic direction with promising efficacy and an acceptable safety profile for IMTUB with ALK fusion. Further clinical investigation is needed to identify its efficacy and safety.
Authors
- Dawen Sui (ORCID: https://orcid.org/0000-0002-8956-478X)
- Hong Ren
- Fei Chen (ORCID: https://orcid.org/0000-0003-3895-6318)
- Xi Chen (ORCID: https://orcid.org/0000-0002-9064-4963)
- Qi Cheng (ORCID: https://orcid.org/0000-0003-2600-6366)
- Zhiyi Zhang (ORCID: https://orcid.org/0000-0001-8345-6588)
Institutions
- Jilin Province Tumor Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.3389/fonc.2025.1481602
- Citations
- 1
- Primary Topic
- IgG4-Related and Inflammatory Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.67